The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
BILLERICA, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), today announced the decision of its Board of Directors to cancel the special cas...
BILLERICA, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), announced today that its board of directors has set September 26, 2023 as the r...
BILLERICA, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), a technology company providing life sciences instrumentation and research servic...
SeqLL (NASDAQ: SQL ) stock is on the rise Monday with heavy trading despite a lack of news from the molecule sequencing technology company. Getting into that trading, some 1.7 million shares of SQL s...
Shares of SeqLL Inc. SQL, -38.69% more than doubled on heavy volume ahead of Friday's open, in the wake of the genetic sequencing company's announcement earlier in the week about an product developmen...
SeqLL (NASDAQ: SQL ) stock is taking off on Friday morning despite a lack of news from the forensic company. Instead, it looks like traders can thank heavy trading for the boost to SQL's stock price t...
SeqLL (NASDAQ: SQL ) stock is seeing massive gains on Tuesday after signing a new contract with a government agency. Specifically, the company has signed a two-year Cooperative Research and Developmen...
BILLERICA, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research servi...
WOBURN, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:SQL; SQLLW), a development-stage life sciences instrumentation and research services company eng...